Clinical trials: Sitagliptin, completed
Type 2 Diabetes
TriMaster: Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes.
The aim of this project is to identify subgroups of patients with type 2 diabetes that respond well or poorly to particular drugs based on particular clinical characteristics such as their weight or kidney function, to enable…
- Trial name
- TriMaster (NCT02653209)
- Testing
- Sitagliptin - DPP4i, Canagliflozin - SGLT2i, Pioglitazone - TZD
- Where
- United Kingdom
- Volunteers
- 525 people
- Sponsor
- Royal Devon and Exeter NHS Foundation Trust
Type 2 Diabetes
MAGE of Anagliptin Compared With Sitagliptin With Type 2 Diabetes Mellitus
An exploratory study to evaluate the Effect of Improving Glycemic Variability of Anagliptin Compared with Sitagliptin in Patients with Type 2 Diabetes Mellitus
- Trial name
- ACACIA (NCT04810507)
- Testing
- Anagliptin BID Treatment
- Where
- South Korea
- Volunteers
- 89 people
- Sponsor
- JW Pharmaceutical
Type2 Diabetes
GA 6: The Blood Glucose-lowering Effect of Glucose-dependent Insulinotropic Polypeptide
This study will investigate if the effect of DPP-4 inhibitors is mediated in part by Glucose-dependent insulinotropic polypeptide.
- Trial name
- NCT03845179
- Testing
- GIP receptor antagonist, DPP-4 inhibitor
- Where
- Denmark
- Volunteers
- 12 people
- Sponsor
- University Hospital, Gentofte, Copenhagen
Type 2 Diabetes
Study of Sulphonylurea Synergy With DPP4 Inhibitors
The Study of Sulphonylurea Synergy with DPP4 Inhibitors (SSS Study) will establish whether a very low dose of sulphonylurea will have a synergistic role on augmentation of insulin secretion when given in combination with a DPP4…
- Trial name
- SSS (NCT04192292)
- Testing
- Sulfonylurea, DPP4 Inhibitor
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- University of Dundee
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)
This trial is conducted in Africa, Asia, Europe and South America. The aim of the trial is to compare the effect of once-weekly dosing of two dose levels of semaglutide versus sitagliptin 100 mg once-daily on glycaemic control…
- Trial name
- SUSTAIN (NCT03061214)
- Testing
- Semaglutide 0.5 mg, Semaglutide 1.0 mg, Sitagliptin
- Where
- 67 sites in Brazil, China and 5 more
- Volunteers
- 868 people
- Sponsor
- Novo Nordisk A/S
Pharmacological Action
Sitagliptin and the Risk for Hypoglycaemia in Type 2 Diabetes Patients
Sitagliptin, through its effects on sensitizing alpha-cell sensitivity to glucose, can initiate counter-regulatory glucagon responses at higher glycemic thresholds, thus reducing the number of clinically apparent hypoglycemic…
- Trial name
- NCT03359590
- Testing
- Sitagliptin 100 mg
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH
Myocardial Infarction, Unstable Angina Pectoris
Beta-cell Function in Glucose Abnormalities and Acute Myocardial Infarction
A three months, double-blind, randomised, parallel-group study evaluating the efficacy of sitagliptin (Januvia™) versus placebo on beta-cell function in patients with newly detected glucose abnormalities and acute myocardial…
- Conditions
- Myocardial Infarction, Unstable Angina Pectoris, Diabetes Mellitus, Impaired Glucose Tolerance
- Trial name
- BEGAMI (NCT00627744)
- Testing
- Sitagliptin
- Where
- 2 sites in Sweden
- Volunteers
- 85 people
- Sponsor
- Karolinska Institutet
Diabetes Mellitus, Type 2
A Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM
This is a double-blind, placebo-controlled, multiple ascending dose study to evaluate the safety, tolerability, PK and PD of DA-1241 in healthy male subjects and subjects with T2DM
- Trial name
- NCT03646721
- Testing
- DA-1241, Sitagliptin
- Where
- 4 sites in United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Dong-A ST Co., Ltd.
Graft vs Host Disease, Hematopoietic Stem Cell Transplantation
Sitagliptin for Prevention of Acute Graft Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
Primary Objective Evaluate the efficacy of sitagliptin in reducing the incidence of grade II-IV acute Graft Versus-Host Disease (GvHD) by day +100 post-transplant in patients undergoing allogeneic hematopoietic stem cell…
- Trial name
- NCT02683525
- Testing
- Sitagliptin
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Sherif S. Farag
Diabetes Mellitus, Type 2
Efficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
This is a 2-3 period parallel group study with an adaptive element in Type 2 diabetes patients receiving vildagliptin as add-on therapy to metformin
- Trial name
- NCT00860288
- Testing
- Vildagliptin, Metformin, Sitagliptin
- Where
- 187 sites in Argentina, Austria and 19 more
- Volunteers
- 1,988 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2
Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency
This clinical trial is designed to provide additional information on the safety and tolerability of vildagliptin (50 mg once daily (qd)) and sitagliptin (25 mg qd) when used in patients with type 2 diabetes mellitus(T2DM) and…
- Trial name
- NCT00616811
- Testing
- vildagliptin, Sitagliptin
- Where
- 79 sites in United States
- Volunteers
- 148 people
- Sponsor
- Novartis
Diabetes Mellitus, Type 2, Renal Insufficiency
Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study)
This clinical trial is designed to provide additional information on the safety and tolerability of vildagliptin (50 mg once daily (qd)) and sitagliptin (25 mg qd) when used in patients with type 2 diabetes mellitus(T2DM) and…
- Trial name
- NCT00770081
- Testing
- vildagliptin, sitagliptin
- Where
- 87 sites in United States
- Volunteers
- 75 people
- Sponsor
- Novartis
Type II Diabetes
Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763
This study is a three part study to assess the safety and efficacy of LEZ763 on normal healthy volunteers and patients with Type 2 Diabetes.
- Trial name
- NCT01619332
- Testing
- Sitagliptin, LEZ763
- Where
- 6 sites in United States
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes Mellitus
A Study to Assess the Pharmacokinetics and the Ability for Pediatric Participants With Type 2 Diabetes to Swallow MK-0431A XR Tablets (MK-0431A-296)
The purpose of this study is to assess: 1. the safety and tolerability of two sitagliptin 50 mg/metformin 1000 mg XR tablets in pediatric participants with type 2 diabetes mellitus (T2DM), aged 10 to 17 years 2.
- Trial name
- NCT01557504
- Testing
- Sitagliptin/metformin XR, Metformin, Thyroid hormone
- Volunteers
- 25 people
- Sponsor
- Merck Sharp & Dohme LLC
Platelet Aggregation During Acute Myocardial Infarction
DPP-4 Inhibitors and Acute Myocardial Infarction:Effects on Platelet Function
Cardiovascular events are the main cause of mortality in diabetic patients ,on the other hand,during an acute myocardial infarction(AMI),hyperglycemia increases mortality and is related to different pathophysiologic processes.
- Trial name
- NCT02377388
- Testing
- sitagliptin OR saxagliptin
- Where
- Brazil
- Volunteers
- 74 people
- Sponsor
- University of Sao Paulo General Hospital
Type 2 Diabetes Mellitus
Study to Evaluate the Efficacy of Acarbose,Metformin,Sitagliptin Combination Treatment in DM Patients
Primary objective To evaluate the efficacy of Acarbose add-on therapy on glucose control in subjects with type 2 diabetes inadequately controlled with Metformin and Sitagliptin combination therapy.
- Trial name
- NCT01490918
- Testing
- Acarbose
- Where
- South Korea
- Volunteers
- 165 people
- Sponsor
- The Catholic University of Korea
Diabetes Mellitus
SNP Study of DPP-4 and GLP-1R in Chinese People (Including Diabetes Patients)
Incretin-based therapy is currently one of the most popular diabetes treatment approaches. However, differences of response ware found in previous studies.
- Trial name
- NCT03108521
- Testing
- Sitagliptin
- Where
- China
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Sichuan Provincial People's Hospital
Healthy
Pharmacokinetic Characteristics of GLH1SM Extended Release Tablets in Healthy Volunteers(Fed)
Crossover study to compare the pharmacokinetic characteristics of GLH1SM sustained release tablet and Janumet XR tablet in fed condition
- Trial name
- NCT03927170
- Testing
- Janumet XR tablet 100/1000 mg, GLH1SM tablet 100/1000 mg
- Where
- South Korea
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- GL Pharm Tech Corporation
Psoriasis, Type 2 Diabetes Mellitus
Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial.
The primary purpose of this study is to determine if sitagliptin (Januvia®) improves psoriasis severity after 16 weeks of treatment in 20 participants with both psoriasis and type 2 diabetes mellitus.
- Trial name
- DIP (NCT01991197)
- Testing
- Sitagliptin, Gliclazide
- Where
- 2 sites in Ireland
- Volunteers
- 20 people
- Sponsor
- University College Dublin
Type 2 Diabetes Mellitus
Sitagliptin Therapy and Kinetics of Inflammatory Markers
Inflammatory processes are increasingly being recognized as a critical step in the pathogenesis of both diabetes and heart disease and may constitute a biological link between the two diseases.
- Trial name
- NCT02536248
- Testing
- Sitagliptin
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Laval University